Nasal High-Flow Therapy for Primary Respiratory Support in Preterm Infants
Calum T Roberts, Louise S Owen, Brett J Manley, Dag H Froisland, Susan M Donath, Kim M Dalziel, Margo A Pritchard, David W Cartwright, Clare L Collins, Atul Malhotra, Peter G Davis, HIPSTER Trial Investigators
New England Journal of Medicine | MASSACHUSETTS MEDICAL SOC | Published : 2016
BACKGROUND: Treatment with nasal high-flow therapy has efficacy similar to that of nasal continuous positive airway pressure (CPAP) when used as postextubation support in neonates. The efficacy of high-flow therapy as the primary means of respiratory support for preterm infants with respiratory distress has not been proved. METHODS: In this international, multicenter, randomized, noninferiority trial, we assigned 564 preterm infants (gestational age, ≥28 weeks 0 days) with early respiratory distress who had not received surfactant replacement to treatment with either nasal high-flow therapy or nasal CPAP. The primary outcome was treatment failure within 72 hours after randomization. Noninfer..View full abstract
Related Projects (1)
Funded by the National Health and Medical Research Council and others; Australian New Zealand Clinical Trials Registry number, ACTRN12613000303741.